Navigation Links
iMedica Partners With Colorado Medical Society To Offer Electronic Health Record, Practice Management Solutions
Date:3/31/2009

Collaboration Builds on State-wide Commitment to Share Electronic Health Information

DALLAS, March 31 /PRNewswire/ -- iMedica Corporation, a leading developer of healthcare software solutions for physician practices, announced today that it has become a member benefit partner of Colorado Medical Society (CMS), the state's largest physician-based association representing more than 7,000 members.

The relationship comes on the heels of the $19 billion in upcoming federal stimulus funds for health information technology, as well as a national commitment to provide everyone in the U.S. with an electronic health record (EHR) by 2014. The partnership also reinforces Colorado's priority to support the sharing of electronic health information across organizations.

As part of the terms of the agreement, CMS member physicians will receive preferred pricing on all iMedica products, as well as the opportunity to participate in live educational seminars designed to highlight the benefits, efficiencies and improved functionality that an EHR and practice management (PM) solution can bring to a medical practice. The need is especially great in troubled economic times when physicians face reduced reimbursement and a decline in fully insured patients.

"Physicians who live in the third most technologically evolved state in the nation are quickly adopting EHR's to improve practice efficiency, cost-effectiveness and patient satisfaction, and iMedica is proud to introduce its solutions to CMS members," said Michael Nissenbaum, President and CEO of iMedica. "iMedica stands out from other EHR vendors because of its unequaled technology platform and adaptability. Our product makes healthcare information accessible and available to p
'/>"/>

SOURCE iMedica Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. iMedica Corporation Announces the Release of Patient Relationship Manager 2009
2. iMedica Corporation Announces Release of Patient Relationship Manager 2009
3. iMedica and Imagetek Team up to Ease Transition to Paperless Medical Practice
4. iMedica and Imagetek Team Up to Ease Transition to Paperless Medical Practice
5. ORBIS International Receives Donated PASCAL(R) Photocoagulator From OptiMedica
6. iMedica Announces Agreement with Misys
7. WallSt.net (www.wallst.net) Updates Investment Community Through All-New Interview With digiMedical Solutions
8. JLL Partners Announces Completion of Acquisition of PharmaNet
9. Australias Healthinc and AMICAS Announce Exclusive Partnership
10. VIDEO from Medialink and Bausch & Lomb: Bausch & Lomb Partners With Visual Therapy to Help Women Nationwide See a New You
11. Bausch & Lomb Partners With Visual Therapy to Help Women Nationwide See a New You
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3The American Academy of Pediatrics Names Lu Ann Papile M D FAAP as Chair of the Fetus and Newborn Committee 50871 1The American Academy of Pediatrics Names Lu Ann Papile M D FAAP as Chair of the Fetus and Newborn Committee 50871 2The American Academy of Pediatrics Names Lu Ann Papile M D FAAP as Chair of the Fetus and Newborn Committee 50871 3Nutrition 21 Launches New Innovative PRESCRIPTIX 28TM 29 Nutraceuticals Product Line 50867 1Nutrition 21 Launches New Innovative PRESCRIPTIX 28TM 29 Nutraceuticals Product Line 50867 2Nutrition 21 Launches New Innovative PRESCRIPTIX 28TM 29 Nutraceuticals Product Line 50867 3Nutrition 21 Launches New Innovative PRESCRIPTIX 28TM 29 Nutraceuticals Product Line 50867 4Nutrition 21 Launches New Innovative PRESCRIPTIX 28TM 29 Nutraceuticals Product Line 50867 5AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 1AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 2AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 3AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 4